Marshall Wace
PYXS icon

Marshall Wace’s Pyxis Oncology PYXS Stock Holding History

Marshall Wace’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
830,544
+476,127
+134% +$910K ﹤0.01% 1739
2026
Q1 		$517K Sell
354,417
-35,347
-9% -$53.3K ﹤0.01% 2436
2025
Q4 		$448K Buy
+389,764
New +$1.37M ﹤0.01% 2282
2025
Q3 		– Sell
-147,771
Closed -$163K – 3308
2025
Q2 		$163K Buy
+147,771
New +$166K ﹤0.01% 2487
2025
Q1 		– Sell
-157,953
Closed -$246K – 3010
2024
Q4 		$246K Buy
157,953
+41,594
+36% +$120K ﹤0.01% 2292
2024
Q3 		$427K Buy
116,359
+106,359
+1,064% +$372K ﹤0.01% 1975
2024
Q2 		$33.1K Sell
10,000
-123,576
-93% -$520K ﹤0.01% 2463
2024
Q1 		$569K Buy
+133,576
New +$562K ﹤0.01% 1882

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace's PYXS Position: Q2 2026 in Review

Marshall Wace increased its Pyxis Oncology (PYXS) stake by 134% in Q2 2026, buying an estimated $910K and bringing the position to 830,544 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Marshall Wace first reported a position in PYXS in Q1 2024 and has held it in 8 quarters since. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Marshall Wace held 830,544 shares of Pyxis Oncology worth $2.5M as of Q2 2026.
  • Marshall Wace bought 476,127 Pyxis Oncology shares in Q2 2026, an estimated $910K.
  • Pyxis Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1739 holding.
  • Marshall Wace first reported a position in Pyxis Oncology in Q1 2024 and has held it in 8 quarters since.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.